Hsp90 activation and cell cycle regulation

Cell Cycle

Volumn 3, Issue 12, 2004, Pages 1530-1536

  Burrows, Francis ^a   Zhang, Hong ^a   Kamal, Adeela ^a  

^a BIOGEN   (United States)

Author keywords

Anticancer drugs; Cancer; Cell cycle; Heat shock protein 90; Selectivity

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DOCETAXEL; GEFITINIB; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 90; IRINOTECAN; PACLITAXEL; PROTEIN INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB;

BINDING AFFINITY; CANCER; CELL CYCLE; CELL CYCLE PHASE; HUMAN; MITOSIS INHIBITION; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 17144377442     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.12.1277     Document Type: Review

References (78)

1. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003; 3:213-7.
2. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003; 228:111-33.
3. Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004; 82:488-99.
4. Picard D. Hsp90 interactors. www.picard.ch/DP/downloads/Hsp90interactors. pdf 2004.
5. Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004; 10:83-90.
6. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther 2002; 2:3-24.
7. Smith DF, Schowalter DB, Kost SL, Toft DO. Reconstitution of progesterone receptor with heat shock proteins. Mol Endocrinol 1990; 4:1704-11.
8. Kosano H, Stensgard B, Charlesworth MC, McMahon N, Toft D. The assembly of progesterone receptor-hsp90 complexes using purified proteins. J Biol Chem 1998; 273:32973-9.
9. Gress TM, Muller-Pillasch F, Weber C, Lerch MM, Friess H, Buchler M, Beger HG, Adler G. Differential expression of heat shock proteins in pancreatic carcinoma. Cancer Res 1994; 54:547-51.
10. Mileo AM, Fanuele M, Battaglia F, Scambia G, Benedetti-Panici P, Mancuso S, Ferrini U. Selective over-expression of mRNA coding for 90 KDa stress-protein in human ovarian cancer. Anticancer Res 1990; 10:903-6.
11. Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC, Luqmani YA. Clinical and biological significance of HSP89a in human breast cancer. Int J Cancer 1992; 50:409-15.
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
13. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994; 91:8324-8.
14. Miller P, DiOrio C, Moyer M, Schnur RC, Bruskin A, Cullen W, Moyer JD. Depletion of the erbB-2 gene product p 185 by benzoquinoid ansamycins. Cancer Res 1994; 54:2724-30.
15. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996; 271:22796-801.
16. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: A unique therapeutic opportunity. Mol Cancer Ther 2004; 3:1021-30.
17. Workman P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: Unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2003; 2:131-8.
18. Egorin MJ, Sentz DL, Zuhowski EG, Dobson JM, Schulte TW, Neckers LM, et al. PC3 human prostrate xenograft retention of, and oncoprotein modulation by 17-(allylamino)-17-demothoxygeldanamycin(17AAG) in vivo. Proc Am Assoc Cancer Res 1999; 40:3409.
19. Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM, Egorin MJ. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2- dimethylamino) ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 2004.
20. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 2001; 8:289-99.
21. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17- demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998; 42:273-9.
22. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425:407-10.
23. Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, Spampinato C, Modrich P, Chiosis G. Targeting wide-range oncogenic transformation via PU24FC1, a specific inhibitor of tumor Hsp90. Chem Biol 2004; 11:787-97.
24. Jerome V, Vourc'h C, Baulieu EE, Catelli MG. Cell cycle regulation of the chicken hsp90a expression. Exp Cell Res 1993; 205:44-51.
25. Galea-Lauri J, Latchman DS, Katz DR. The role of the 90-kDa heat shock protein in cell cycle control and differentiation of the monoblastoid cell line U937. Exp Cell Res 1996; 226:243-54.
26. Nakai A, Ishikawa T. Cell cycle transition under stress conditions controlled by vertebrate heat shock factors. EMBO J 2001; 20:2885-95.
27. Lange BM, Bachi A, Wilm M, Gonzalez C. Hsp90 is a core centrosomal component and is required at different stages of the centrosome cycle in Drosophila and vertebrates. EMBO J 2000; 19:1252-62.
28. Sherr CJ. The Pezcoller lecture: Cancer cell cycles revisited. Cancer Res 2000; 60:3689-95.
29. Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 1997; 8:287-301.
30. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriprionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 1998; 273:29864-72.
31. Kim HR, Lee CH, Choi YH, Kang HS, Kim HD. Geldanamycin induces cell cycle arrest in K562 erythroleukemic cells. IUBMB Life 1999; 48:425-8.
32. Bedin M, Gaben AM, Saucier C, Mester J. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest. Int J Cancer 2004; 109:643-52.
33. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003; 15:419-24.
34. Mahony D, Parry DA, Lees E. Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells. Oncogene 1998; 16:603-11.
35. Stepanova L, Leng X, Parker SB, Harper JW. Mammalian p50Cdc37 is a prorein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 1996; 10:1491-502.
36. Munoz MJ, Jimenez J. Genetic interactions between Hsp90 and the Cdc2 mitotic machinery in the fission yeast Schizosaccharomyces pombe. Mol Gen Genet 1999; 261:242-50.
37. Mattson DMJ, Bradbury CM, Sieck LK, Coleman CN, Gius D. Geldanamycin inhibition of HSP90 as a target in cell cycle regulation. Proc Natl Acad Sci USA 2003; 44:782.
38. Aligue R, Akhavan-Niak H, Russell P. A role for Hsp90 in cell cycle control: Weel tyrosine kinase activity requires interaction with Hsp90. EMBO J 1994; 13:6099-106.
39. Goes FS, Martin J. Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mikl, Weel and Swel. Eur J Biochem 2001; 268:2281-9.
40. de Career G, do Carmo Avides M, Lallena MJ, Glover DM, Gonzalez C. Requirement of Hsp90 for centrosomal function reflects its regulation of Polo kinase stability. EMBO J 2001; 20:2878-84.
41. de Career G. Hear shock prorein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner. Cancer Res 2004; 64:5106-12.
42. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC, Sessa WC, Altieri DC. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003; 100:13791-6.
43. Lange BM, Rebollo E, Herold A, Gonzalez C. Cdc37 is essential for chromosome segregation and cytokinesis in higher eukaryotes. EMBO J 2002; 21:5364-74.
44. An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000; 11:355-60.
45. Scholz GM. The molecular chaperone Hsp90 is required for signal transduction by wild-type Hck and maintenance of its constitutively active counterpart. Cell Growth Differ 2001; 12:409-17.
46. Blagosklonny MV. Hsp-90-associated oncoproteins: Multiple targets of geldanamycin and its analogs. Leukemia 2002; 16:455-62.
47. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002; 21:1159-66.
48. Munster PN, Srethapakdi M, Moasser MM, Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 2001; 61:2945-52.
49. 1 arrest. Cancer Res 2000; 60:3940-6.
50. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylarnino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001; 61:4003-9.
51. McIlwrath AJ, Vasey PA, Ross GM, Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res 1994; 54:3718-22.
52. Liu XL, Xiao B, Yu ZC, Guo JC, Zhao QC, Xu L, Shi YQ, Fan DM. Down-regulation of Hsp90 could change cell cycle distribution and increase drug sensitivity of tumor cells. World J Gastroenterol 1999; 5:199-208.
53. Argiris A, Wang CX, Whalen SG, DiGiovanna MP. Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res 2004; 10:1409-20.
54. Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Vigano L, Fumagalli M, Menard S, Gianni L. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J Cell Physiol 2004; 198:259-68.
55. 1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer Res 2003; 63:4028-36.
56. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10:262-7.
57. Evan GI, Vousden KH. Prolifecation, cell cycle and apoptosis in cancer. Nature 2001; 411:342-8.
58. Torres K, Horwitz SB. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998; 58:3620-6.
59. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002; 8:878-84.
60. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001; 15:1537-43.
61. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters. Clin Cancer Res 2001; 7:2228-36 (2155-2158).
62. Nguyen DM, Lorang D, Chen GA, Stewart JH, Tabibi E, Schrump DS. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: In vitro and in vivo analysis. Ann Thorac Surg 2001; 72:371-8, discussion 378-9.
63. McCollum A, Toft DO, Erlichman C. Geldanamycin enhances cisplatin cytotoxicity through loss of Akt activation in A549 cells. Clin Cancer Res 2003; 9:6178s.
64. Vasilevskaya IA, Rakitina TV, O'Dwyer PJ. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: Differential caspase activation as a basis for interaction. Cancer Res 2003; 63:3241-6.
65. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92:1472-89.
66. Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three Akts. Genes Dev 1999; 13:2905-27
67. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998; 94:471-80.
68. Ali A, Bharadwaj S, O'Carroll R, Ovsenek N. HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes. Mol Cell Biol 1998; 18:4949-60.
69. Redmond T, Sanchez ER, Bresnick EH, Schlesinger MJ, Toft DO, Pratt WB, Welsh MJ. Immunofluorescence colocalization of the 90-kDa heat-shock protein and microtubules in interphase and mitotic mammalian cells. Eur J Cell Biol 1989; 50:66-75.
70. SSchuh S, Yonemoto W, Brugge J, Bauer VJ, Riehl RM, Sullivan WP, Toft DO. A 90,000-dalton binding protein common to both steroid receptors and the Rous sarcoma virus transforming protein, pp60v-src. J Biol Chem 1985; 260:14292-6.
71. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003; 3:377-83.
72. Whitesell L, Bagatell R, Falsey R. The stress response: Implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 2003; 3:349-58.
73. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003; 63:2139-44.
74. Sano M. Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons. Neuropharmacology 2001; 40:947-53.
75. Marx J. Cell biology. Do centrosome abnormalities lead to cancer? Science 2001; 292:426-9.
76. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL, Peters JM. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochoremicrotubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003; 161:281-94.
77. Yan Y, Sardana V, Xu B, Homnick C, Halczenko W, Buser CA, Schaber M, Hartman GD, Huber HE, Kuo LC. Inhibition of a mitotic motor protein: Where, how, and conformational consequences. J Mol Biol 2004; 335:547-54.
78. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res 2001; 7:2168-81.